92 related articles for article (PubMed ID: 24671363)
1. Enhanced intracellular targeting of tumor-specific antigens: you can lead a horse to water, but….
Berger DH
JAMA Surg; 2014 May; 149(5):457-8. PubMed ID: 24671363
[No Abstract] [Full Text] [Related]
2. MAGE-A3 with cell-penetrating domain as an efficient therapeutic cancer vaccine.
Batchu RB; Gruzdyn O; Potti RB; Weaver DW; Gruber SA
JAMA Surg; 2014 May; 149(5):451-7. PubMed ID: 24671426
[TBL] [Abstract][Full Text] [Related]
3. Dendritic cell immuno-therapy in disseminated parathyroid carcinoma.
Schott M; Feldkamp J; Schattenberg D; Seissler J; Scherbaum WA
Lancet; 1999 Apr; 353(9159):1188-9. PubMed ID: 10210012
[No Abstract] [Full Text] [Related]
4. The impact of dendritic cell-tumor fusion cells on cancer vaccines - past progress and future strategies.
Kajihara M; Takakura K; Ohkusa T; Koido S
Immunotherapy; 2015; 7(10):1111-22. PubMed ID: 26507578
[TBL] [Abstract][Full Text] [Related]
5. Potential role of dendritic cell vaccination with MAGE peptides in gastrointestinal carcinomas.
Tanaka F; Haraguchi N; Isikawa K; Inoue H; Mori M
Oncol Rep; 2008 Nov; 20(5):1111-6. PubMed ID: 18949409
[TBL] [Abstract][Full Text] [Related]
6. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
[TBL] [Abstract][Full Text] [Related]
7. SSX antigens as tumor vaccine targets in human sarcoma.
Ayyoub M; Brehm M; Metthez G; Talbot S; Dutoit V; Taub RN; Keohan ML; Gure AO; Chen YT; Williamson B; Jungbluth AA; Old LJ; Hesdorffer CS; Valmori D
Cancer Immun; 2003 Oct; 3():13. PubMed ID: 14533943
[TBL] [Abstract][Full Text] [Related]
8. DC-based cancer vaccines.
Gilboa E
J Clin Invest; 2007 May; 117(5):1195-203. PubMed ID: 17476349
[TBL] [Abstract][Full Text] [Related]
9. MAGE-A3: an immunogenic target used in clinical practice.
Esfandiary A; Ghafouri-Fard S
Immunotherapy; 2015; 7(6):683-704. PubMed ID: 26100270
[TBL] [Abstract][Full Text] [Related]
10. Enhanced antitumor immunity by targeting dendritic cells with tumor cell lysate-loaded chitosan nanoparticles vaccine.
Shi GN; Zhang CN; Xu R; Niu JF; Song HJ; Zhang XY; Wang WW; Wang YM; Li C; Wei XQ; Kong DL
Biomaterials; 2017 Jan; 113():191-202. PubMed ID: 27816821
[TBL] [Abstract][Full Text] [Related]
11. MRI tracks cancer-vaccine cells.
Gould P
Lancet Oncol; 2006 Jan; 7(1):16. PubMed ID: 16408371
[No Abstract] [Full Text] [Related]
12. Phase II trial of dendritic cells loaded with antigens from self-renewing, proliferating autologous tumor cells as patient-specific antitumor vaccines in patients with metastatic melanoma: final report.
Dillman RO; Selvan SR; Schiltz PM; McClay EF; Barth NM; DePriest C; de Leon C; Mayorga C; Cornforth AN; Allen K
Cancer Biother Radiopharm; 2009 Jun; 24(3):311-9. PubMed ID: 19538053
[TBL] [Abstract][Full Text] [Related]
13. Photosensitizer and Light Pave the Way for Cytosolic Targeting and Generation of Cytosolic CD8 T Cells Using PLGA Vaccine Particles.
Bruno C; Waeckerle-Men Y; Håkerud M; Kündig TM; Gander B; Johansen P
J Immunol; 2015 Jul; 195(1):166-73. PubMed ID: 26019274
[TBL] [Abstract][Full Text] [Related]
14. Migration of dendritic cell based cancer vaccines: in vivo veritas?
Adema GJ; de Vries IJ; Punt CJ; Figdor CG
Curr Opin Immunol; 2005 Apr; 17(2):170-4. PubMed ID: 15766677
[TBL] [Abstract][Full Text] [Related]
15. Construction of a fusion plasmid containing the PSCA gene and cytotoxic T-lymphocyte associated antigen-4 (CTLA-4) and its anti-tumor effect in an animal model of prostate cancer.
Mai TJ; Ma R; Li Z; Bi SC
Braz J Med Biol Res; 2016 Oct; 49(11):e5620. PubMed ID: 27783810
[TBL] [Abstract][Full Text] [Related]
16. Targeting of antigens to activated dendritic cells in vivo cures metastatic melanoma in mice.
Mahnke K; Qian Y; Fondel S; Brueck J; Becker C; Enk AH
Cancer Res; 2005 Aug; 65(15):7007-12. PubMed ID: 16061687
[TBL] [Abstract][Full Text] [Related]
17. High frequency of antitumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens.
Germeau C; Ma W; Schiavetti F; Lurquin C; Henry E; Vigneron N; Brasseur F; Lethé B; De Plaen E; Velu T; Boon T; Coulie PG
J Exp Med; 2005 Jan; 201(2):241-8. PubMed ID: 15657293
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy based on dendritic cells pulsed with CTPFoxM1 fusion protein protects against the development of hepatocellular carcinoma.
Su H; Li B; Zheng L; Wang H; Zhang L
Oncotarget; 2016 Jul; 7(30):48401-48411. PubMed ID: 27351282
[TBL] [Abstract][Full Text] [Related]
19. [Tumor vaccines and peptide-loaded dendritic cells (DCs)].
Schummer V; Flindt S; Hinz T
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2015 Nov; 58(11-12):1254-8. PubMed ID: 26349562
[TBL] [Abstract][Full Text] [Related]
20. [General principles and first clinical trials of therapeutic vaccines against cancer].
Baurain JF; Van der Bruggen P; Van den Eynde BJ; Coulie PG; Van Baren N
Bull Cancer; 2008 Mar; 95(3):327-35. PubMed ID: 18390413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
